Status: Recruiting
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: iCell Gene TherapeuticsUpdated: Jan 22, 2025Locations: 1
Eligibility criteria
1. Age: 18~60 years old; 2. Diagnosed with immune thrombocytopenia associated wi...